Announcements Trials

Browse Landscape

Phase

Status

Unknown 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 4 Gynecologic 4 Sarcoma 3 Gastrointestinal 3 Other hematologic neoplasm 2 Genitourinary 2 Breast 2 Other solid neoplasm 1 Myeloid 1 Lymphoid 1 Head & Neck 1 Dermatologic 1

Conditions

Interventions

pembrolizumab 70 Nivolumab 47 Ipilimumab 27 Specimen Handling 15 Magnetic Resonance Spectroscopy 15 trametinib 14 Biopsy 13 dabrafenib 11 cemiplimab 11 avelumab 11 Cyclophosphamide 11 binimetinib 10 Radiotherapy 9 CTLA-4 Antigen 9 fludarabine 8 encorafenib 7 atezolizumab 7 Radiosurgery 7 Immunoglobulin G 7 Disulfides 7 Cisplatin 7 fludarabine phosphate 6 durvalumab 6 tislelizumab 5 relatlimab 5 lenvatinib 5 dostarlimab 5 Pemetrexed 5 Paclitaxel 5 Introns 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × ceralasertib × Dermatologic × Clear all

NCT05061134 2025-07-31

MONETTE

AstraZeneca

Phase 2 Active not recruiting

194 enrolled 21 charts

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡